Nobivac Canine 1-DAPPvL2+Cv (Canada)This page contains information on Nobivac Canine 1-DAPPvL2+Cv for veterinary use.
The information provided typically includes the following:
- Nobivac Canine 1-DAPPvL2+Cv Indications
- Warnings and cautions for Nobivac Canine 1-DAPPvL2+Cv
- Direction and dosage information for Nobivac Canine 1-DAPPvL2+Cv
Nobivac Canine 1-DAPPvL2+CvThis treatment applies to the following species:
CANINE DISTEMPER-ADENOVIRUS TYPE 2-CORONAVIRUS-PARAINFLUENZA-PARVOVIRUS VACCINE Modified Live & Killed Virus
LEPTOSPIRA CANICOLA-ICTEROHAEMORRHAGIAE BACTERIN
FOR ANIMAL USE ONLY
IN THE ABSENCE OF A VETERINARIAN-CLIENT-PATIENT RELATIONSHIP, FEDERAL REGULATIONS PROHIBIT THE RELABELING, REPACKAGING, RESALE OR REDISTRIBUTION OF THE INDIVIDUAL CONTENTS OF THIS PACKAGE.
Nobivac® Canine 1-DAPPvL2+Cv vaccine is a combination vaccine that unites the benefits of Nobivac® Canine 1-DAPPvL2 and Nobivac® Canine 1-Cv in one vaccination.
Nobivac Canine 1-DAPPvL2 vaccine is a modified live virus vaccine which is combined with an inactivated Leptospira canicola and Leptospira icterohaemorrhagiae bacterin for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper virus, canine adenovirus type 1 (hepatitis), canine adenovirus type 2 (respiratory disease), canine parainfluenza virus, and canine parvovirus and against Leptospiral disease due to L. canicola or L. icterohaemorrhagiae. Data indicate the development of corneal opacity is not associated with the use of this product.
Nobivac Canine 1-Cv vaccine (feline enteric coronavirus) is a killed virus vaccine for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine coronavirus infection. The coronavirus has been chemically inactivated and combined with an adjuvant designed to enhance the immune response.
Dosage and Administration
Shake the Nobivac Canine 1-Cv vial and transfer its contents to the Nobivac Canine 1-DAPPvL2 vial aseptically. Mix gently until dissolved. Use entire contents immediately after rehydration.
Inject one dose (1mL) subcutaneously or intramuscularly.
The initial dose may be given at 6 weeks of age or older. Repeat at 2 to 4 week intervals until the dog is 12 weeks of age. A minimum of two doses is required for primary immunization. Annual revaccination with one dose is recommended. Following the advice of the American Veterinary Medical Association on Vaccination Principles, an appropriate revaccination program for individual animals should be made based upon veterinarian-client-patient relationships.
● Store at 2° - 7°C.
● Do not freeze.
● Do not mix with other vaccines.
● Use new, non-chemically sterilized needles and syringes.
● Burn vaccine container and all unused contents.
● Contains gentamicin and thimerosal as preservatives.
● Vaccinate only healthy, non-parasitized dogs.
● Do not vaccinate pregnant bitches.
● The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.
● The age at which maternal antibody for canine parvovirus no longer interferes with the development of active immunity varies according to the bitch’s titer and quantity of colostral antibodies absorbed by the puppy.
Merck Animal Health, division of Intervet Inc.
Omaha, NE 68103 USA
U.S. Veterinary License No. 165A
1 800 224-5318 (USA)
1 866 683-7838 (Canada)
For patent information:
NAC No.: 1208231.3
Intervet Canada Corp.
16750 ROUTE TRANSCANADIENNE, KIRKLAND, QC, H9H 4M7
|Fax:||Toll-free 888-498-4444; local 514-428-7014|
|Every effort has been made to ensure the accuracy of the Nobivac Canine 1-DAPPvL2+Cv information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-10-31